Stereotaxis ((STXS)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Stereotaxis’ latest earnings call struck a cautious but hopeful tone as management balanced substantial strategic milestones against near-term financial strain. Executives highlighted a series of pivotal regulatory wins and promising early adoption of new products, yet investors were reminded of declining revenue, ongoing losses, and the cash demands of a complex business transformation.
Regulatory Wins Build a New Robotics Ecosystem
Stereotaxis underscored a string of recent regulatory approvals as the foundation for its next phase of growth. The company secured four U.S. FDA decisions, including PMA approval for its MAGIC catheter and clearance for the Synchrony digital cockpit, alongside approvals in Europe and China, significantly broadening its addressable market.
MAGIC Catheter Shows Early Clinical Traction
Management highlighted the launch of MAGIC, its proprietary therapeutic ablation catheter, as a central achievement this quarter. Early procedures at multiple U.S. hospitals delivered successful outcomes, including in complex congenital heart disease cases that had failed manual catheter treatments, with demand already outpacing available supply.
High-Value Disposable Revenue Opportunity
The company emphasized that MAGIC-driven disposable sales could meaningfully reshape its revenue mix. Initial U.S. procedures generated more than $8,000 per case in many instances and never less than $5,000, while a European hospital ordered about $100,000 of disposables for a single month, as Stereotaxis targets production of roughly 500 catheters per month by year-end.
Synchrony and Genesys X Expand the Digital and Capital Portfolio
Stereotaxis is pairing disposables with new capital and digital tools, led by Synchrony, its FDA-cleared digital surgery cockpit that has begun shipping and is projected to deliver $3 million in revenue in 2026. The Genesys X robotic system, designed for installation in existing cath labs without major construction, has a growing pipeline as the company aims to activate at least five Genesis programs this year.
Robocath Deal Anchors Long-Term Robotics Vision
The announced acquisition of Robocath was framed as a strategic move to deepen Stereotaxis’ robotics capabilities. Robocath’s complementary mechanism of action for endovascular navigation is expected to align with the company’s ambition for remote, automated robotic treatment across stroke and cardiovascular care.
Reaffirmed Revenue Ramp and 2026 Targets
Despite present volatility, management reiterated its outlook for double-digit revenue growth in 2026, with annual revenue expected to exceed $40 million. The company anticipates sequential quarterly gains, forecasting that both the third and fourth quarters will surpass $10 million in revenue, underpinned by MAGIC disposables and new product launches.
Margins and Cost Control Amid Transformation
Financially, Stereotaxis reported a consolidated gross margin of 60%, with recurring revenue margins at 66% and system margins at 39%, reflecting the mixed economics of its portfolio. Adjusted operating expenses were held essentially flat year over year at $6.7 million, signaling cost discipline even as the company invests in manufacturing and commercialization.
Strengthened but Limited Cash Position
On the balance sheet, Stereotaxis ended the quarter with $14.6 million in cash and no debt, describing this as sufficient but tight relative to its ambitious plans. Management used an at-the-market equity program at higher share prices to bolster liquidity and is pursuing nondilutive and nondebt financing options to navigate the Robocath integration and product ramp.
Revenue Contraction Highlights Near-Term Pressure
Headline results showed the strain of the transition, with first-quarter revenue falling to $6.3 million from $7.5 million a year ago, a decline of about 16%. System revenue dropped sharply to $1.3 million from $2.0 million, while recurring revenue slipped to $5.0 million from $5.5 million, underscoring softer capital sales and procedure volumes.
J&J Transition Obscures Underlying Disposable Ramp
A key headwind came from the winding down of Stereotaxis’ historical catheter partnership with Johnson & Johnson, which management described as messy. Supply issues during this transition pressured procedure volumes and recurring revenue and, in the company’s view, temporarily obscure the early ramp of its new MAGIC disposable business in reported numbers.
Capacity Constraints Delay MAGIC Revenue Recognition
MAGIC production challenges in the quarter further limited reported growth, as a process shift early in the year constrained output and pushed much of March’s manufacturing into April revenue. With demand currently exceeding supply, management stressed that achieving the target of about 500 catheters per month is critical to unlocking the expected disposable revenue ramp.
Losses and Cash Burn Remain a Concern
The company continues to operate in the red, posting a $6.0 million operating loss and a $5.9 million net loss, both modestly worse than the prior year. Adjusted operating loss rose to $2.9 million, while negative free cash flow nearly doubled to $3.5 million, highlighting increased cash burn amid the product and capacity build-out.
Soft System Sales Expose Capital-Side Risk
System sales were notably weak, with only $1.3 million in revenue from capital systems during the quarter, despite a stated pipeline and backlog for Genesis and Genesys X. Management acknowledged that converting this pipeline depends on pioneering accounts willing to adopt systems that rely on nonintegrated X-ray compatibility, which may slow the pace of new installations.
Execution and Market Adoption Risks Persist
Beyond manufacturing and capital sales, Stereotaxis faces broader execution risk as it pushes a new model of robotic navigation and digital surgery. Success will require careful integration and validation of Genesys X in real-world cath labs, while simultaneously scaling MAGIC catheter usage, capital placements, and the newly acquired Robocath platform.
Guidance Underscores Ambitious but Conditional Ramp
Looking ahead, management’s guidance hinges on translating today’s portfolio into tangible growth, including surpassing $40 million in revenue next year and delivering more than $10 million in revenue in both the third and fourth quarters. The plan assumes at least $3 million in Synchrony revenue, MAGIC production reaching roughly 500 units per month, and expanding high-margin disposable revenue per procedure, with the expectation that operating losses will decline as recurring revenue builds.
Stereotaxis’ earnings call painted a picture of a company at an inflection point, pairing transformative regulatory and product milestones with visible financial strain and execution risk. Investors will now watch whether the company can scale MAGIC production, convert its capital pipeline, and integrate Robocath fast enough to deliver on its ambitious 2026 revenue and profitability targets.